What are KRAS G12C inhibitor drugs?

KRAS G12C inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting KRAS G12C). 0 are currently marketed, with 4 more in clinical development.

KRAS G12C inhibitor

0 marketed 3 in Phase 3 1 in Phase 2

This page covers all KRAS G12C inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting KRAS G12C.

Targets

KRAS G12C

Phase 3 pipeline (3)

AMG 510 · Criterium, Inc. · Oncology
AMG 510 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.
MRTX849 · Mirati Therapeutics Inc. · Oncology
MRTX849 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.
RMC-6236 · Revolution Medicines, Inc. · Oncology
RMC-6236 is a selective inhibitor of KRAS G12C mutations that blocks oncogenic signaling in cancer cells.

Phase 2 pipeline (1)

DCL-101 vs Golytely · Dark Canyon Laboratories, LLC · Oncology
DCL-101 is a small molecule that targets the KRAS G12C mutation, inhibiting the KRAS protein's ability to promote cancer cell growth.